

### Summary

In this domain of the REMAP-CAP trial, participants meeting the platform entry criteria for REMAP-CAP admitted to participating intensive care units with suspected or microbiological testing-confirmed COVID-19 infection will be randomized to one of two interventions:

- Local standard venous thromboprophylaxis
- Therapeutic anticoagulation with intravenous unfractionated heparin or subcutaneous low molecular weight heparin

This domain will enroll patients only in the pandemic infection is suspected or proven (PISOP) stratum and be analyzed in the Pandemic Statistical Model as outlined from the Pandemic Appendix to Core (PA<sub>TC</sub>).

At this participating site the following interventions have been selected within this domain:

- ☐ Local standard venous thromboprophylaxis
- ☐ Therapeutic anticoagulation with intravenous unfractionated heparin or subcutaneous low molecular weight heparin

Is the site participating in this COVID-19 Therapeutic Anticoagulation Domain? YES/NO

Name Site:

Name PI:

Date:

Signature: